Morgan Stanley lowered the firm’s price target on Halozyme (HALO) to $75 from $79 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- CoreWeave initiated, Shopify downgraded: Wall Street’s top analyst calls
- Skye Bioscience, Halozyme enter collaboration, license agreement
- Halozyme, Skye Bioscience announce global collaboration, license agreement
- Rybrevant FASPRO Approval and ENHANZE Royalties Reset Halozyme’s Long-Term Growth Outlook, Supporting a Buy Rating and $90 Target
- Johnson and Johnson’s Rybrevant Faspro combination in NSCLC approved by FDA